docetaxel anhydrous has been researched along with Leukocyte Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baeuerle, PA; Eiermann, W; Göppel, G; Hanusch, CA; Lang, A; Marschner, N; Oruzio, D; Rüttinger, D; Schlimok, G; Schmidt, M; Schuler, M; Sebastian, M; Steger, GG; Wolf, A; Wolf, C | 1 |
1 trial(s) available for docetaxel anhydrous and Leukocyte Disorders
| Article | Year |
|---|---|
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion Molecules; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Female; Humans; Leukocyte Disorders; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2012 |